The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example




Cost-effectiveness, Economic evaluation, Health technology assessment (HTA), Osteoarthritis (OA), Quality-adjusted life years (QALY)


Osteoarthritis (OA) is a degenerative joint disease with a substantial global burden, causing chronic pain and reduced quality of life. Managing OA efficiently while maximizing healthcare resources is crucial. Health economics and health technology assessment (HTA) are central tools providing a framework to evaluate the clinical, economic, and ethical aspects of healthcare technologies and interventions. This article presents some insights into the role of health economics and the HTA process in OA management. It also illustrates an example of cost-effectiveness analysis in a specific healthcare context, on the basis of a recent clinical trial involving hyaluronic acid treatment for knee OA. While HTA offers valuable insights, it faces challenges like data availability and resource constraints. Integrating health economics into decision-making can enhance patient care and allocate resources effectively in OA and other healthcare domains.


Download data is not yet available.


Vos T, Lim SS, Abbafati C, et al; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. PMID:33069326 DOI:

Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-233. PMID:31908163 DOI:

Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437-441. PMID:24662640 DOI:

Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759. PMID:31034380 DOI:

Mobasheri A, Saarakkala S, Finnilä M, et al. Recent advances in understanding the phenotypes of osteoarthritis [version 1; peer review: 2 approved]. F1000Res 2019;8(F1000 Faculty Rev):2091. DOI:

Bruyère O, Cooper C, Arden N, et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging. 2015;32(3):179-187. PMID:25701074 DOI:

Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016;59(5-6):333-339. PMID:27546496 DOI:

Long H, Liu Q, Yin H, et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74(7):1172-1183. PMID:35233975 DOI:

Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthritis Cartilage. 2022;30(1):10-16. PMID:34023527 DOI:

Alami S, Boutron I, Desjeux D, et al. Patients’ and practitioners’ views of knee osteoarthritis and its management: a qualitative interview study. PLoS One. 2011;6(5):e19634. PMID:21573185 DOI:

Kaplan RM, Babad YM. Balancing influence between actors in healthcare decision making. BMC Health Serv Res. 2011;11(1):85. PMID:21504599 DOI:

Radinmanesh M, Ebadifard Azar F, Aghaei Hashjin A, Najafi B, Majdzadeh R. A review of appropriate indicators for need-based financial resource allocation in health systems. BMC Health Serv Res. 2021;21(1):674. PMID:34243784 DOI:

Li N, Cornelissen D, Silverman S, et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. PharmacoEconomics. 2021;39(2):181-209. PMID:33026634 DOI:

Hiligsmann M, Kanis JA, Compston J, et al. Health technology assessment in osteoporosis. Calcif Tissue Int. 2013;93(1):1-14. PMID:23515633 DOI:

Bruyère O, Reginster JY, Honvo G. Health economic evaluation of a high and low molecular weight hyaluronic acid formulation for the treatment of knee osteoarthritis. Post hoc analyses from a randomized clinical trial. Rheumatol Ther. 2022;9(4):1119-1128. PMID:35655027 DOI:

Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. PMID:31278997 DOI:

Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. PMID:31126594 DOI:

Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis–from evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4)(suppl):S3-S11. PMID:26806188 DOI:

Wang CP, Lee WC, Hsieh RL. Effects of repeated co-injections of corticosteroids and hyaluronic acid on knee osteoarthritis: a prospective, double-blind randomized controlled trial. Am J Med. 2022;135(5):641-649. PMID:34958762 DOI:

He WW, Kuang MJ, Zhao J, et al. Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: ameta-analysis. Int J Surg. 2017;39:95-103. PMID:28137554 DOI:

Migliore A, Procopio S. Effectiveness and utility of hyaluronic acid in osteoarthritis. Clin Cases Miner Bone Metab. 2015;12(1):31-33. PMID:26136793 DOI:

Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244-258. PMID:18601792 DOI:

Goodman CS. Introduction to health technology assessment. The Lewin Group; 2004.

Dieleman JL, Sadat N, Chang AY, et al; Global Burden of Disease Health Financing Collaborator Network. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016-40. Lancet. 2018;391(10132):1783-1798. PMID:29678341 DOI:

Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736. PMID:21479777 DOI:

Finch AP, Meregaglia M, Ciani O, Roudijk B, Jommi C. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med. 2022;292:114519. PMID:34736804 DOI:

Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7-22. PMID:28833869 DOI:

Bouckaert N, Cleemput I, Devriese S, Gerkens S. An EQ-5D-5L value set for Belgium. PharmacoEconom Open. 2022;6(6):823-836. PMID:35927410 DOI:

Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. PharmacoEconomics. 2018;36(6):663-674. PMID:29460066 DOI:

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840. PMID:3068365

Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW. A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. J Rheumatol. 2007;34(3):534-542. PMID:17343301 DOI:

Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press; 2015:464.

Briggs A, Claxton K,Sculpher M. Decision modelling for health economic evaluation. Oxford University Press; 2006. DOI:

Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):iii-iv, 1-192. PMID:15544708 DOI:

Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677-687. PMID:16491461 DOI:

Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? PharmacoEconomics. 2000;17(5):445-459. PMID:10977387 DOI:

Migliore A, Blicharski T, Plebanski R, et al. Knee osteoarthritis pain management with an innovative high and low molecular weight hyaluronic acid formulation (HA-HL): a randomized clinical trial. Rheumatol Ther. 2021;8(4):1617-1636. PMID:34462887 DOI:

Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018;11(1):1447828. PMID:29564962 DOI:

O’Rourke B, Werkö SS, Merlin T, Huang LY, Schuller T. The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint. Int J Technol Assess HealthCare. 2020;36(1):1-4. PMID:31775943 DOI:



How to Cite

Hiligsmann, M., & Bruyère, O. (2024). The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example. Global and Regional Health Technology Assessment, 11(1), 75–81.
Received 2023-10-11
Accepted 2024-02-29
Published 2024-04-03